A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations. Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associat...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	The Journal of Clinical Investigation
المؤلفون الرئيسيون:	David H. McDermott, Daniel Velez, Elena Cho, Edward W. Cowen, John J. DiGiovanna, Diana V. Pastrana, Christopher B. Buck, Katherine R. Calvo, Pamela J. Gardner, Sergio D. Rosenzweig, Pamela Stratton, Melissa A. Merideth, H. Jeffrey Kim, Carmen Brewer, James D. Katz, Douglas B. Kuhns, Harry L. Malech, Dean Follmann, Michael P. Fay, Philip M. Murphy
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	American Society for Clinical Investigation 2023-10-01
الموضوعات:	Clinical trials Immunology
الوصول للمادة أونلاين:	https://doi.org/10.1172/JCI164918